结核分枝杆菌和鸟分枝杆菌复合群在巨噬细胞内的传代改变了这些微生物的药物敏感性，这是通过使用巨噬细胞和II型肺泡上皮细胞进行细胞内药敏试验确定的。
Intramacrophage passage of Mycobacterium tuberculosis and M. avium complex alters the drug susceptibilities of the organisms as determined by intracellular susceptibility testing using macrophages and type II alveolar epithelial cells.
作者信息
Tomioka Haruaki, Sato Katsumasa, Sano Chiaki, Sano Keisuke, Shimizu Toshiaki
机构信息
Department of Microbiology and Immunology, Shimane Medical University, Izumo, Shimane 693-8501, Japan.
出版信息
Antimicrob Agents Chemother. 2002 Feb;46(2):519-21. doi: 10.1128/AAC.46.2.519-521.2002.
Abstract
Mycobacterium tuberculosis and M. avium complex strains given intramacrophage passage (I-type) were compared with those cultured in a liquid medium (E-type) for their drug susceptibilities when they were replicating in Mono-Mac-6 macrophages or A-549 cells. Their intracellular susceptibilities to rifalazil, clarithromycin, and levofloxacin were decreased more in I-type organisms than in E-type organisms, except that their rifalazil susceptibility inside A-549 cells was markedly increased in I-type organisms.
摘要
将经巨噬细胞内传代培养的结核分枝杆菌和鸟分枝杆菌复合群菌株（I型）与在液体培养基中培养的菌株（E型）进行比较，观察它们在单核巨噬细胞-6或A-549细胞中复制时的药敏情况。I型菌株对利福拉齐、克拉霉素和左氧氟沙星的细胞内药敏性比E型菌株下降得更多，不过I型菌株在A-549细胞内对利福拉齐的药敏性显著增加。
相似文献
1
Intramacrophage passage of Mycobacterium tuberculosis and M. avium complex alters the drug susceptibilities of the organisms as determined by intracellular susceptibility testing using macrophages and type II alveolar epithelial cells.
Antimicrob Agents Chemother. 2002 Feb;46(2):519-21. doi: 10.1128/AAC.46.2.519-521.2002.
2
3
Antimicrobial activities of levofloxacin, clarithromycin, and KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium complex replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines.
Int J Antimicrob Agents. 2000 Sep;16(1):25-9. doi: 10.1016/s0924-8579(00)00163-1.
4
5
Antimicrobial activities of cinnamyl rifamycin derivatives, T-9 and T-11, against Mycobacterium tuberculosis and Mycobacterium avium complex (MAC) with special reference to the activities against intracellular MAC.
Microbiol Immunol. 2006;50(8):621-3. doi: 10.1111/j.1348-0421.2006.tb03836.x.
6
Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Antimicrob Agents Chemother. 2000 Feb;44(2):283-6. doi: 10.1128/AAC.44.2.283-286.2000.
7
Antimicrobial activities of benzoxazinorifamycin (KRM-1648) and clarithromycin against Mycobacterium avium-intracellulare complex within murine peritoneal macrophages, human macrophage-like cells and human alveolar epithelial cells.
J Antimicrob Chemother. 1999 Mar;43(3):351-7. doi: 10.1093/jac/43.3.351.
8
Antimicrobial activity of picolinic acid against extracellular and intracellular Mycobacterium avium complex and its combined activity with clarithromycin, rifampicin and fluoroquinolones.
J Antimicrob Chemother. 2006 Jan;57(1):85-93. doi: 10.1093/jac/dki418. Epub 2005 Nov 22.
9
Prospects for development of new antimycobacterial drugs.
J Infect Chemother. 2000 Mar;6(1):8-20. doi: 10.1007/s101560050043.
10
Antimicrobial activities of clarithromycin, gatifloxacin and sitafloxacin, in combination with various antimycobacterial drugs against extracellular and intramacrophage Mycobacterium avium complex.
Int J Antimicrob Agents. 2002 Feb;19(2):139-45. doi: 10.1016/s0924-8579(01)00473-3.
引用本文的文献
1
Therapeutic efficacy of rifalazil (KRM-1648) in a M. ulcerans-induced Buruli ulcer mouse model.
PLoS One. 2022 Oct 6;17(10):e0274742. doi: 10.1371/journal.pone.0274742. eCollection 2022.
2
A Rabbit Model to Study Antibiotic Penetration at the Site of Infection for Nontuberculous Mycobacterial Lung Disease: Macrolide Case Study.
Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0221221. doi: 10.1128/aac.02212-21. Epub 2022 Jan 31.
3
Preclinical Models of Nontuberculous Mycobacteria Infection for Early Drug Discovery and Vaccine Research.
Pathogens. 2020 Aug 6;9(8):641. doi: 10.3390/pathogens9080641.
4
Effect of mycobacterial secretory proteins on the cellular integrity and cytokine profile of type II alveolar epithelial cells.
Lung India. 2012 Oct;29(4):313-8. doi: 10.4103/0970-2113.102796.
5
Comparative study for the virulence of Mycobacterium avium isolates from patients with nodular-bronchiectasis- and cavitary-type diseases.
Eur J Clin Microbiol Infect Dis. 2010 Jul;29(7):801-6. doi: 10.1007/s10096-010-0930-2. Epub 2010 May 4.
6
Mycobacterium avium-intracellulare contamination of mammalian cell cultures.
In Vitro Cell Dev Biol Anim. 2009 Jan-Feb;45(1-2):75-90. doi: 10.1007/s11626-008-9143-8. Epub 2008 Oct 15.
本文引用的文献
1
Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis.
Antimicrob Agents Chemother. 2001 Jul;45(7):1972-6. doi: 10.1128/AAC.45.7.1972-1976.2001.
2
Antimicrobial activities of levofloxacin, clarithromycin, and KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium complex replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines.
Int J Antimicrob Agents. 2000 Sep;16(1):25-9. doi: 10.1016/s0924-8579(00)00163-1.
3
Evasion of host cell defense mechanisms by pathogenic bacteria.
Curr Opin Immunol. 2001 Feb;13(1):37-44. doi: 10.1016/s0952-7915(00)00179-5.
4
Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648.
Arch Immunol Ther Exp (Warsz). 2000;48(3):183-8.
5
A coat protein on phagosomes involved in the intracellular survival of mycobacteria.
Cell. 1999 May 14;97(4):435-47. doi: 10.1016/s0092-8674(00)80754-0.
6
Antimicrobial activities of benzoxazinorifamycin (KRM-1648) and clarithromycin against Mycobacterium avium-intracellulare complex within murine peritoneal macrophages, human macrophage-like cells and human alveolar epithelial cells.
J Antimicrob Chemother. 1999 Mar;43(3):351-7. doi: 10.1093/jac/43.3.351.
7
Interactions between Mycobacterium tuberculosis and host cells: are mycobacterial sugars the key?
Trends Microbiol. 1998 Aug;6(8):328-35. doi: 10.1016/s0966-842x(98)01301-8.
8
Growth within macrophages increases the efficiency of Mycobacterium avium in invading other macrophages by a complement receptor-independent pathway.
Infect Immun. 1997 May;65(5):1916-25. doi: 10.1128/iai.65.5.1916-1925.1997.
9
Comparison of in vitro models for the study of Mycobacterium tuberculosis invasion and intracellular replication.
Infect Immun. 1996 Jul;64(7):2673-9. doi: 10.1128/iai.64.7.2673-2679.1996.
10
Mycobacterium tuberculosis invades and replicates within type II alveolar cells.
Infect Immun. 1996 Apr;64(4):1400-6. doi: 10.1128/iai.64.4.1400-1406.1996.
Zotero 插件